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Recently, the interest in natural products for the treatment of 
cancer is increasing because they are the pre-screened 
candidates. In the present study, we demonstrate the thera-
peutic effect of celastrol, a triterpene extracted from the root 
bark of Chinese medicine on gastric cancer. The proliferation 
of AGS and YCC-2 cells were most sensitively decreased in six 
kinds of gastric cancer cell lines after the treatment with 
celastrol. Celastrol inhibited the cell migration and increased 
G1 arrest in cell-cycle populations in both cell lines. The 
treatment with celastrol significantly induced autophagy and 
apoptosis and increased the expression of autophagy and 
apoptosis-related proteins. We also found an increase in 
phosphorylated AMPK following a decrease in all phos-
phorylated forms of AKT, mTOR and S6K after the treatment 
with celastrol. Moreover, gastric tumor burdens were reduced 
in a dose-dependent manner by celastrol administration in a 
xenografted mice model. Taken together, celastrol distinctly 
inhibits the gastric cancer cell proliferation and induces auto-
phagy and apoptosis. [BMB Reports 2014; 47(12): 697-702]
INTRODUCTION
Gastric cancer is the second leading cause of cancer related 
death and surgical resection is considered the mainstay of 
curative treatment, though it can only be performed in a 
small subgroup of patients (1). Most patients diagnosed 
with advanced gastric cancer or recurrence within five 
years after surgery will receive chemotherapeutic treatment 
(2, 3). Chemotherapy clearly improves the gastric cancer 
survival, but the treatment is limited by the high rates of ad-
verse effects and rapid therapeutic resistance (4). Therefore, 
there has been an ongoing development of novel ther-
apeutic regimens that can overcome these adverse effects 
and resistance to cancer therapy. 
　Recently, numerous studies have indicated that natural rem-
edies have therapeutic effects on inflammatory, metabolic and 
neoplastic diseases (5). The primary benefit of prescreened 
candidates of natural compounds is there process of natural se-
lection and that they are already used for some purposes. Of 
them, celastrol has been of great interest due to its therapeutic 
potential (6). Celastrol, a quinine methide triterpenoid, is the 
most abundant bioactive compound derived from the root of 
Trypterigium wilfordii Hook L, also known as “Thunder of 
God Vine” (7). It has been reported to be an inhibitor of lipid 
peroxidation (8) and to have anti-arthritis and anti-Alzheimer 
effects due to the regulation of cytokine release (9-11). 
Moreover, celastrol has been found to suppress tumor ini-
tiation, progression and metastasis in a wide variety of tumor 
cells and in vivo cancer models (12). Studies of the therapeutic 
mechanism have revealed that it inhibits the heat shock pro-
tein 90 (Hsp90) and proteasomes (13, 14) and can suppress 
the NF-κB signaling pathway (15), AKT/mTOR pathway (16, 
17), MAPK pathway (18) and VEGFR expression (19) in various 
cancers. 
　However, the therapeutic effects of celastrol on gastric can-
cer have not yet been clearly demonstrated. In this study, we 
measured the gastric cancer cell proliferation and induction of 
apoptosis and autophagy after celastrol treatment. We also de-
termined the effects of celastrol on cell-survival-related signal-
ing proteins. Additionally, we used the celastrol treatment as 
part of a gastric cancer xenograft mouse model and analyzed 
its tumor suppressive effects in vivo.
RESULTS
Celastrol inhibited cell proliferation and migration and 
induced cell cycle arrest and apoptosis in gastric cancer cells
To determine the cytotoxic effect of celastrol in gastric cancer, 
we treated six different gastric cancer cell lines with different 
doses of celastrol (Fig. 1A). After 3 days of treatment, the cell 
proliferation decreased at concentrations of celastrol up to 1 
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Fig. 1. Celastrol inhibited cell pro-
liferation and migration and induced 
cell cycle arrest and apoptosis in gas-
tric cancer cells. (A) Detection of cell 
proliferation by MTT assay after the 
treatment with celastrol using different 
doses (0, 0.25 0.5, and 1 μM) for 48 
hours in six gastric cancer cell lines. 
(B) AGS cell migration was detected 
using a wound-healing assay. AGS 
and YCC-2 cells were scratched and 
treated with different doses (0, 0.25, 
0.5 and 1 μM) for 24 hours and pic-
tures were taken. (C) AGS and YCC-2 
cells were treated with celastrol using 
different doses (0, 0.25, 0.5 and 1 
μM) for 48 hours. Cell populations in 
each phase of the cell cycle were de-
tected by PI staining. Apoptosis in-
duction was detected by annexin V 
staining.
μM. The IC50 of AGS cells was detected as being as low as 
0.25 μM celastrol and the IC50 of YCC-2 was 0.5 μM celastrol. 
Moreover, the wound-healing properties, representing migra-
tion in both AGS and YCC-2 cell lines were found to be sig-
nificantly impaired at 0.25 μM and 0.5 μM celastrol, re-
spectively (Fig. 1B). The effects of celastrol treatment on the 
cell cycle were analyzed and the findings are presented in Fig. 
1C. After 48 hours of treatment with different doses of celastrol 
in AGS and YCC-2 cells, a significant increase of cells in the 
G1 phase was detected at a concentration of 0.25 μM and the 
SubG1 phase was detected at the concentration of 1 μM after 
the treatment with celastrol in both cell lines (Fig. 1C). Also an 
apoptosis induction was detected after celastrol treatment in 
AGS and YCC-2 cells. Significant apoptosis was induced after 
the treatment with 0.5 μM celastrol in both cell lines (Fig. 
1D).These findings suggest that celastrol is a potent inhibitor of 
gastric cancer cell proliferation and migration.
Celastrol increased the expression of cell-cycle and apoptosis 
related proteins and phosphorylated AMPK
The expression of cell-cycle-related proteins, such as p21 and 
p27 was markedly increased and the expression of cyclin D1 
was decreased by the treatment with celastrol ranging from 
concentrations of 0.25 μM to 1 μM (Fig. 2A). Moreover, ex-
pression levels of apoptosis-related proteins were analyzed in 
AGS cells (Fig. 2B). Noticeable increases in cytochrome C and 
Bax were detected after the treatment with 0.5 μM celastrol, 
whereas apoptosis inhibitory proteins such as survivin, Bcl-2, 
and Bcl-xl drastically decreased after treatment with the same 
concentration of celastrol. The activation of caspases was 
measured by cleavage of the pro-forms and cleaved forms of 
PARP, caspase-3, caspase-9 and caspase-8 were decreased by 
the treatment with 0.5 μM celastrol. It is known that celastrol 
activates AMP-activated protein kinase (AMPK) and inhibits 
AKT/mammalian target of rapamycin (mTOR) signaling path-
ways to induce autophagy and apoptosis (20, 21). Therefore, 
we demonstrated the phosphorylation status of these proteins 
after the treatment with 0.5 μM celastrol in AGS cells (Fig. 2C). 
As early as 15 minutes after the initiation of treatment with 0.5 
μM celastrol, significant increases in phosphorylated AMPK 
were detected in both cell lines (the data of YCC-2 were not 
shown). Substantial downstream targets, such as phosphory-
lated AKT, phosphorylated mTOR and phosphorylated S6K 
were also decreased at similar time points. Therefore, celastrol 
has an effect on the cell-survival-related signaling pathway in 
gastric cancer cell lines as early as 15 minutes after treatment.
Celastrol induced autophagy and increased expression of the 
autophagy-related proteins
To determine the autophagy effect in gastric cancer cells (Fig. 
3), we prepared stable RFP-tagged LC-3 expressed AGS cells 
and treated them with different doses of celastrol for 1 day. 
Compared with the 0.25 μM of celastrol that were needed to 
induce the G1 arrest, the same concentration of celastrol in-
creased the number of autophagosomes in the cytosol (Fig. 
3A).At higher concentrations of 0.5 and 1 μM celastrol, AGS 
cells were smaller and appeared to be undergoing the apop-
totic process. The autophagy-related proteins LC3 I, II, ATG5 
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Fig. 2. Celastrol increased expression 
cell-cycle and apoptosis related pro-
teins and phosphorylated AMPK. AGS 
and YCC-2 cells were treated with ce-
lastrol using different doses (0, 0.25, 
0.5 and 1 μM) for 48 hours. (A) p21 
and p27 as a CDK inhibitor and cy-
clin D1 were detected by Western 
blot analysis. (B) Apoptosis-related pro-
teins from AGS cell lysates were de-
tected by Western blot analysis. (C) 
AGS cells were treated with 0.5 μM 
of celastrol at several time points (0, 
15, 30 and 120 minutes) and cell ly-
sates were prepared for Western blot-
ting analysis. All experiments were in-
dividually performed more than twice 
and present representative data.
Fig. 3. Celastrol induced autophagy in 
gastric cancer cells. (A) AGS cells ex-
pressing stable RFP-tagged LC-3 were 
treated with celastrol at different doses 
(0, 0.25, 0.5 and 1 μM) for 24 hours. 
RFP-tagged LC-3 was detected by fluo-
rescent microscopy. DAPI staining was 
used to detect nuclei. (B) AGS and 
YCC-2 cells were treated with differ-
ent doses of celastrol (0, 0.25, 0.5 
and 1 μM) for 24 hours. Autophagy- 
induced proteins were detected by 
Western blot analysis. All experiments 
were individually performed more than
twice and present representative data. 
and Beclin1 were increased after the treatment with 0.25 μM 
celastrol, whereas ATG7 was increased at the highest concen-
tration of celastrol (1 μM) in both AGS and YCC-2 cell lines 
(Fig. 3B). Therefore, it is likely that celastrol induced autoph-
agy to initiate the G1 arrest of gastric cancer cells. Additio-
nally, celastrol induced both autophagy and apoptosis, leading 
to an inhibition of gastric cancer cell growth.
Administration of celastrol reduced gastric tumor burdens in 
xenografted mice
We confirmed the therapeutic effects of celastrol in vivo in a 
mouse model (Fig. 4). We prepared AGS cell xenografted mice 
as described previously (22), and orally administered 1 mg/kg 
or 2 mg/kg of celastrol until mice were sacrificed. Gastric tu-
mor burdens in xenografted mice were significantly reduced 
by celastrol administration in a dose-dependent manner (Fig. 
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Fig. 4. Celastrol inhibited the growth 
of gastric tumors in a mouse xeno-
grafted model. AGS cells xenografts 
were prepared as described in the 
“Materials and Methods” session. After 
10 days of tumor growth to obtain 
palpable tumors, mice were orally ad-
ministered 100 μl of control saline, 1 
mg/kg/day celastrol or 2 mg/kg/day of 
celastrol for 12 days and then sacri-
ficed for analyses. (A) Tumor volumes 
were measured every 2 or 3 days and
are graphically presented. (B) Gastric 
tumors were obtained and pictures 
were taken. (C) Immunohistochemical 
analysis of the expression of phospho-
rylated AMPK, phosphorylated AKT 
and phosphorylated mTOR. H&E sta-
ining was performed.
4A). After mice were sacrificed, tumors were obtained and 
measured. Smaller tumor sizes were observed in mice ad-
ministered with 2 mg/kg celastrol compared to others (Fig. 4B). 
The immunohistochemical analysis revealed that the celastrol 
administration increased the phosphorylated AMPK and de-
creased both phosphorylated AKT and phosphorylated mTOR 
in gastric tumors (Fig. 4C). Therefore, we confirmed the results 
of our in vitro studies using an in vivo model and found that 
celastrol induced the activation of AMPK and deactivation of 
AKT and mTOR. It is likely that these signaling pathways play 
a role in the reduction of gastric cancer cell growth.
DISCUSSION
Despite declining incidence rates in the United States, gastric 
cancer is one of the most common cancers in the world and 
causes significant morbidity and mortality worldwide (23). 
Patients diagnosed with advanced gastric cancer have a me-
dian survival of only 3 to4 months without chemotherapy (2, 
4, 24). The most common chemotherapeutic regimens are a 
combination of cisplatin and 5-FU and a combination of 5-FU 
and epirubicin. Response rates to these drugs are between 20 
to 40%. However, the duration of responses is quickly less-
ened and there are very few complete responses. Additionally, 
it is important to recognize that the toxicity and side effects are 
not negligible, even in patients with a good functional status. 
In an effort to improve the cancer treatment, there have been 
many studies with the goal of exploring new drugs and im-
proving drug side effects (25).
　In this study, we studied celastrol as a novel candidate de-
rived from natural compounds for the treatment of gastric 
cancer. As previously mentioned, celastrol has been vigorously 
studied to demonstrate its in vitro anti-tumor mechanisms in 
various cancers. It has also been found to suppress tumors in in 
vivo models and the therapeutic effects of celastrol were exam-
ined on the growth and metastasis of melanoma in syngeneic 
and xenograft mouse models (26), human prostate tumor xeno-
grafts (16), ErbB2-overexpressing human breast cancer cell xen-
ografted mice (27) and human glioma xenografted mice (19). 
There are two reports on the antitumor effect of celastrol in gas-
tric cancer (21, 28), but direct studies on the effect of celastrol 
in gastric cancer cells and especially in an in vivo gastric can-
cer mouse model were necessary. In this study, we identified 
the inhibition of cell proliferation and the induction of apopto-
sis and autophagy by the treatment with celastrol. Interestingly, 
IC50 was achieved using a treatment concentration of 1 μM in 
most gastric cancer cell lines, suggesting an effective and ac-
ceptable concentration of celastrol for the use in clinical trials. 
Celastrol also induced autophagy at low doses by as low as a 
0.25 μM in both cell lines. At present, the role of autophagy in 
the restriction of cellular proliferation is controversial (29). 
Nevertheless, it has been reported that autophagy induction 
sensitizes cells for the induction of apoptosis and cell death 
and protects against chemotherapy resistance (30). We also de-
termined that celastrol induced autophagy and initiated G1 
cell-cycle arrest, which likely enhanced the induction of 
apoptosis. However, further mechanistic studies are necessary 
to confirm this conclusion. Another interesting finding is the in-
duction of AMPK phosphorylation by celastrol as early as 15 
minutes after the initiation of treatment. It has been reported 
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that celastrol suppresses the cell viability of MCF-7 through 
AMPK activation which is caused by ROS generation (31). We 
suggest that celastrol induces AMPK activation and suppresses 
AKT and mTOR activation, which then leads to autophagy and 
apoptosis. We are currently under taking mechanistic studies 
on celastrol-induced AMPK activation in gastric cancer. Addi-
tionally, we administered celastrol in a gastric cancer xeno-
grafted mouse model and investigated the significant reduction 
of gastric tumor burdens with an increasing activation of AMPK 
and decreasing activity of AKT and mTOR. Taken together, we 
suggest that celastrol-induced AMPK activation plays an im-
portant role in the inhibition of gastric cancer growth.
　In conclusion, celastrol successfully suppressed the cell pro-
liferation and increased autophagy and apoptosis in gastric 
cancer cells. Therefore, we have undertaken further studies to 
elucidate the molecular mechanisms of celastrol in gastric can-
cer and suggest the further study for a possible application in 
clinical trials with gastric cancer patients.
MATERIALS AND METHODS
Methods of Western blotting, Preparation of gastric cancer 
xenografted mice, and Immunochemical staining analysis are 
available as supplementary materials on BMB Reports online.
Detection of cell proliferation and cell migration
The inhibition of cell proliferation by celastrol was measured 
using an MTT assay. Celastrol was purchased from Cayman 
Chemical (Michigan, USA) and dissolved in dimethyl sulfoxide 
(DMSO). The human stomach adenocarcinoma cell line AGS 
and the gastric carcinoma cell lines MKN1, MKN45, SNU216, 
SNU-668, and YCC-2 were purchased from the Korea Cell Line 
Bank (KCLB, Seoul, Korea). The KCLB authenticates the pheno-
types of these cell lines on a regular basis. The analysis of cell 
proliferation using MTT assay and migration using a wound- 
healing assay was performed as described previously (32).
Assessment of cell cycle, apoptosis and autophagy
AGS and YCC-2 cells were plated onto culture plates and treat-
ed with celastrol. PI staining and annexin V processes were 
performed as described previously (33). For the detection of 
autophagy, RFP-tagged LC-3 lenti-virus was kindly obtained 
from Dr. Ho-Shin Kwak of the National-Cancer-Center of 
Korea. Then, cells were infected using this virus as described 
previously (34). Chamber slide cultured cells were fixed and 
treated with a mounting medium consisting of 4'6-diamid-
ino-2-phenylindole and analyzed by confocal microscopy 
(LSM 520 META; Carl-Zeiss, Jena, Germany).
Statistical analysis
We employed unpaired t-tests to analyze mean tumor volumes 
in xenograft mice as described previously (37). Two tumors 
per mouse were analyzed as different entities. All statistical 
tests were two-sided and values are expressed as means with 
± SD. P-values less than 0.05 were considered statistically 
significant. Statistical analyses were performed using PASW 
Statistics software version 18 (SPSS Inc., Chicago, IL, USA).
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